‘Alien: Earth' Will Explore One of the Franchise's Favorite Questions
The more we hear about Noah Hawley's Alien: Earth series, the more eager we are to start watching it ASAP. Alas, August 12 is a decent chunk of time to keep waiting, but at least we're continuously learning new tidbits about what to expect. Earlier this month, FX and Hulu shared concrete details about the show's plot for the first time; today, we're learning more about its main character, a human-robot hybrid played by Sydney Chandler, and central themes.
The latter won't surprise anyone who's watched any of the Alien movies. At the show's heart will be a question that's threaded through all the entries since Ridley Scott's 1979 original: of all the monsters in the universe, are humans actually the worst?
'Sydney's character is someone who's trying to figure out what her role is in this world and, on some level, the age-old question of, does humanity deserve to survive?,' Hawley explained in a new interview with Entertainment Weekly. The series creator said he took direct inspiration from Ripley (Sigourney Weaver) wondering 'which species is worse' in 1986's Aliens.
'This idea of the horrible things that we do to each other,' Hawley continues. 'Sydney plays a somewhat innocent character who finds herself trying to navigate two kinds of monsters. One is human and the other is from outer space. We do expand on that idea that it's going to be up to the audience which species is worse.'
Chandler's character, who is named Wendy, is innocent because she's literally a child: according to EW, she has 'a child's brain in a bot's body.' That makes her and her fellow hybrids' interactions with the show's Xenomorphs unique.
'Noah took us more into the mindset space,' Chandler told the magazine. 'What is the essence of a kid or a young adult? How do their minds work differently than the adult mind? Kids are so present and they haven't been battered by the world as much as an adult. So they trust their gut and they don't second guess.'
Alien: Earth arrives August 12 on FX and Hulu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
12 minutes ago
- Forbes
Northern Lights Alert: 13 States May See Aurora On Monday And Tuesday
Wisconsin's night sky is glowing with the Northern Lights, as a geomagnetic storm is bringing ... More vibrant pink and green colors. (Photo by Ross Harried/NurPhoto via Getty Images) The Northern Lights may be visible from 13 U.S. states on Monday, June 2 through Tuesday, June 3, 2025, after a G1 geomagnetic storm was forecast by the National Oceanic and Atmospheric Administration. It comes in the wake of an 'extreme' G5 geomagnetic storm last weekend that saw aurora borealis seen from as far south as California. As Earth approaches the solstice on June 21, the U.S. is currently one of the best places to see the Northern Lights. The agency's three-day forecast has a geomagnetic storm, measured at a value of G1 on a scale of G1 to G5, potentially occurring on Monday night through Tuesday morning in North America. NOAA's aurora viewlines have potential aurora displays that are possible in northern U.S. states and Canada. A total of 13 U.S. states have a chance of seeing the aurora on the northern horizon, with those on the U.S.-Canada border having a higher chance. According to NOAA, this display may be seen from Washington, northern Idaho, Montana, northeast Wyoming, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, New York, Vermont, New Hampshire and Maine. Regions closest to the border with Canada will have the highest possibility of seeing the aurora. NOAA's forecast for the aurora viewline on Monday, June 2, 2025. According to NOAA's forecast, the Kp index — which provides a rough guide to the intensity of aurora displays — may reach 5, seeing the auroral oval stretch farther south. Kp 5 equates to a G1-class geomagnetic storm. For a Kp in the range of 3 to 5, 'The aurora will move further from the poles, it will become brighter, and there will be more auroral activity (motion and formations)," according to NOAA. "If you are in the right place, these aurora can be quite pleasing to look at.' The geomagnetic storm on May 10, 2024, which saw aurora as far south as Florida, was rated as G5 and had Kp 9 intensity. It was the most powerful since 2003. Although it's forecast for Monday night through Tuesday morning in North America, exactly when and where aurora becomes visible this week will be down not to predictions but data coming in from NASA's DSCOVR and ACE satellites. Orbiting the sun from around a million miles from Earth, they give a roughly 30-minute warning of aurora displays after measuring the solar wind's speed and magnetic intensity. Check NOAA's 30-minute forecast or use the Glendale App for up-to-the-minute forecasts. People visit St Mary's lighthouse to see the aurora borealis, commonly known as the northern lights, ... More on May 10, 2024 in Whitley Bay, England. (Photo by) If your smartphone has a 'Night Mode' feature, that should be good enough to get a more than impressive souvenir shot of the aurora. It likely means a long exposure of between five and 10 seconds, which will look much better if you do three things: The Northern Lights are caused by the solar wind, a stream of charged particles from the sun interacting with Earth's magnetic field. Although the magnetic field deflects much of it, some charged particles accelerate along the magnetic field lines toward the polar regions, where they collide with oxygen and nitrogen atoms, exciting them and causing them to release energy as light. The possibility of displays of the aurora borealis at more southerly latitudes comes from a spike in solar activity, which is currently at a 23-year high due to the current solar maximum period. Geomagnetic storms and aurora are expected to continue through 2025 and 2026. Wishing you clear skies and wide eyes.
Washington Post
33 minutes ago
- Washington Post
Yarbrough's revenge: How a World Series ring inspired his win for the Yankees over the Dodgers
LOS ANGELES — Ryan Yarbrough picked up a dazzling World Series ring from his time with the Los Angeles Dodgers last season. Then he went out and beat them. The New York Yankees starter pitched one-run ball over six innings, struck out a season-high five and blanked the Dodgers' top four hitters in a 7-3 win Sunday night. 'I feel like I'm in a really good place right now and really trying to continue that,' Yarbrough said. 'I'm having a lot of fun.' The 33-year-old left-hander made 44 relief appearances between the Dodgers and Blue Jays last season. The Dodgers designated him for assignment on July 29 and the next day traded him to Toronto. So even though he wasn't around for their World Series victory over the Yankees last fall, Yarbrough earned a ring. He accepted it from Dodgers general manager Brandon Gomes on Friday behind home plate during batting practice. 'Trying to keep that a little discreet, especially with where we're at now, but kind of cool to be able to get that,' Yarbrough said. He signed a $2 million, one-year deal with New York in March and is 3-0 with a 2.83 ERA this season. Making his first career start against the Dodgers, Yarbrough recorded 17 swings-and-misses — including seven with his sweeper. The top four hitters in Los Angeles' lineup had produced at least one hit in every game this season. That is, until Shohei Ohtani, Teoscar Hernández, Freddie Freeman and Will Smith combined to go 0 for 14 in the series finale against Yarbrough and the Yankees. New York manager Aaron Boone has called Yarbrough a throwback, noting his 6-foot-5 frame creates a 'funky' angle for hitters. 'He's got a lot of ways to get you out. Just when you think he's slowing you down, slowing you down, he's able to speed you up enough,' Boone said. 'It feels like it's hard to get a bead on him.' It certainly was for Ohtani. He struck out on five pitches ranging from 70-86 mph in the first inning, when Yarbrough retired the side in order. Later, he set down 13 of 15 batters before exiting. 'He's not going to light up the radar gun, but all his pitches feel like they get on you,' teammate DJ LeMahieu said. 'His fastballs look like they get on you and his off-speed looks extra slow. He's got good stuff and he knows what he's doing out there.' Yarbrough conceded his familiarity with his ex-teammates helped, too. 'It was just a matter of execution and keeping them off balance and not putting them in counts where they can really hunt for certain pitches,' he said. It was also a big night for LeMahieu, who had his first four-hit game since 2021. He drove in two runs and raised his batting average to .239. The second baseman had three singles and a double on a night when Aaron Judge was the only Yankees player without a hit. 'I feel good. Good to get some results,' LeMahieu said. ___ AP MLB:
Medscape
an hour ago
- Medscape
Centanafadine ‘Clinically Meaningful' for Adult ADHD
LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and 'clinically meaningful' for adult attention-deficit/hyperactivity disorder (ADHD), new research suggested. In a combined analysis of two phase 3 trials with a total of 859 adults, more patients who received the NDSRI had at least an 18-point improvement at week 6 on the ADHD Investigator Symptom Rating Scale (AISRS) total scores compared with patients on placebo. Additionally, a significantly greater percentage of the active treatment groups showed improvement in the measure's hyperactivity/impulsivity and inattention subscales. Lenard A. Adler, MD But we weren't just interested in statistically significant change but in change 'that means something,' said principal investigator Lenard A. Adler, MD, director of the Adult ADHD program and professor of psychiatry at the New York University (NYU) Grossman School of Medicine, New York City. 'In other words: What do we know is a significant amount of change in patients receiving a compound? That's always a question because we want to get patients well and not just better,' Adler told Medscape Medical News . The findings were presented on May 19 at the American Psychiatric Association (APA) 2025 Annual Meeting. A high-dose, pediatric version of the drug was similarly effective for both children and adolescents in two additional phase 3 trials also presented at the meeting by Adler and colleagues. 'Gives a Benchmark' Centanafadine 'is a triple reuptake inhibitor, so it's not a classical stimulant,' said Adler. 'It's a compound that offers a unique profile.' Investigators pooled data from two identically designed phase 3 trials looking at the drug in patients with a primary diagnosis of ADHD. Together, this included 859 adult patients, with a mean age of 35 years (52% men; 80.3% White). The mean baseline total score on the semi-structured AISRS scale was 38.8 ('moderately ill'), with the mean AISRS inattention score 21.6 ('severely ill') and the mean AISRS hyperactivity/impulsivity score 17.2 ('moderately ill'). The AISRS is conducted as an interview between patient and clinician. 'We also recorded data on clinicians' global impression of severity and global impression of change and then used those as anchors to look at the clinically meaningful within-patient change for the AISRS,' co-investigator Caroline Ward, PhD, director of the Global Clinical Development at Otsuka Pharmaceutical Companies, told Medscape Medical News. All participants were randomly assigned to receive centanafadine at 200 mg (n = 287) or 400 mg (n = 287) or a matching placebo (n = 285). Results showed that the mean change on the AISRS total score at week 6 was −12.1 and −12.5 for the centanafadine 200 mg and 400 mg groups, respectively, vs −8.1 for the placebo group ( P = .002 and .0009). In addition, 24% of the 200 mg group and 25.4% of the 400 mg group achieved an 18-point or greater improvement in AISRS total score from baseline to week 6 compared with 15.4% of the placebo group (ratio of response rate [RR], 1.70; P = .002 and RR, 1.71; P = .001, respectively). A 10-point or greater improvement on the AISRS inattention subscale was achieved by 26.1% of the 200 mg group and 23.3% of the 400 mg group compared with 16.5% of the placebo group (RR, 1.71; P = .001 and RR, 1.45; P = .03, respectively); and an 8-point or greater improvement on the hyperactivity/impulsivity subscale was achieved by 26.5% and 28.6% of the 200 mg and 400 mg groups, respectively, compared with 20% of the placebo group (RR, 1.38; P = .03 and RR, 1.47; P = .01, respectively). The 200 mg and 400 mg groups also reached the 'clinically meaningful within-patient change AISRS threshold' for the first time earlier than the placebo group ( P = .0006 and P < .0001, respectively). Looking at meaningful change 'gives clinicians a benchmark,' said Adler. Pediatric Safety and Efficacy The investigators also presented results from two other randomized phase 3 trials that assessed the drug in children between the ages of 6 and 12 years (n = 480; 58% boys) and adolescents between 13 and 17 years (n = 459; 59% boys). Of these, 77% and 81%, respectively, completed their studies. All were from the United States and Canada. The adolescents received high-dose centanafadine (328.8 mg once daily), low-dose centanafadine (164.4 mg once daily), or placebo for 6 weeks. The children received a placebo or a high or low dose of centanafadine, with doses based on their weight. A larger number of children who received high-dose centanafadine had an 18-point or greater improvement at week 6 on the ADHD Rating Scale–5 (ADHD-RS-5) total score compared with the children who received placebo (34.5% vs 23.3%; P = .03), with even stronger effects found in the adolescents (47.7% vs 31.7%; P = .004). A greater number of the high-dose active treatment group vs the placebo group also had at least a 10-point improvement in ADHD-RS-5 inattention subscale scores (children, P = .03; adolescents, P = .003) and at least an 8-point improvement in hyperactivity/impulsivity subscale scores ( P = .04 and .03, respectively). In addition, the mean change from baseline to week 6 on the ADHD-RS-5 total score was −16.3 for the children receiving the high-dose drug vs −10.8 for those receiving placebo ( P = .0008) and was −18.5 vs −14.2 in the adolescents ( P = .0006). When assessing caregiver-rated improvements, investigators found that a greater number of children and adolescents receiving high-dose centanafadine vs placebo achieved at least a 14-point improvement on the Conners 3–Parent Short Inattention T-scores ( P = .02 and .001, respectively) and at least a 13-point improvement on the Conners 3–Parent Short Hyperactivity/Impulsivity T-scores ( P = .02 and .007, respectively). Most treatment-emergent adverse events were deemed to be mild to moderate. The most common adverse events in the high-dose centanafadine group were decreased appetite and rash in the children and decreased appetite, rash, nausea, and headache in the adolescents. Ward reported that data from these studies, along with some they conducted previously and some that are ongoing, will be part of a package they're preparing to send to the US Food and Drug Administration in the near future. Altogether, 'it tells a nice story,' she said. Real-World Data Commenting for Medscape Medical News, Soonjo Hwang, MD, associate professor of psychiatry at the University of Nebraska Medical Center, Omaha, Nebraska, noted that among treatments already available for ADHD, the most well-known are stimulant medications, which 'are purely' dopaminergic reuptake inhibitors. Soonjo Hwang, MD 'That said, norepinephrine, dopamine, and serotonin have a close relationship with each other in the brain. So, if you inhibit one, it will have an impact on the others as well,' said Hwang, who was not involved with the new research. He pointed out that centanafadine has a similar profile to other medication groups, such as antidepressants, that have been assessed previously for ADHD. 'In terms of the mechanism, it's similar to some we've had in the past. Still, it is really important for us to have new tools to treat this disorder because we currently have limited options,' Hwang said. He noted that being 'clinically meaningful' is a concept worth thinking about. 'This was a randomized-controlled clinical trial that [focused] towards more real-world data. And it's important to have data on how the medication performs in a real-world situation before launching it to market,' he said. Hwang added that he'd also like to know, moving forward, how well the medication works in patients with comorbidities, which is common in those with ADHD.
